Cell line · CVCL_0327
Papers79
1 more article gives this line's RRID in its Methods without naming the line nearby, so it is not listed.
1 to 20 of 79
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| PubMed 43000531 | Nat Commun | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Chronic stress activates a hypothalamic vagal circuit to promote hepatocellular carcinoma progression in male mice. | Nat Commun | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Liver-specific amino acid metabolism impacts on efficacy of cancer immunotherapy. | Oncogene | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Fedratinib treatment correlates with suppressed STAT3/AKT/calpain-1 signaling and inhibits hepatocellular carcinoma progression. | Transl Gastroenterol Hepatol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| XIAP inhibition augments personalized neoantigen vaccine-driven antitumor immunity in orthotopic hepatocellular carcinoma. | J Immunother Cancer | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Metabolic Reprogramming of NSUN2-Mediated m5C Modification Promotes the Progression of Hepatocellular Carcinoma by Restricting Natural Killer Cell-Mediated Cytotoxicity. | Cancer Commun (Lond) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Targeting circulating fatty acid-binding protein 4 ameliorates obesity-associated hepatic steatosis. | JHEP Rep | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Mechanosensors Collaborate to Regulate DNA Damage Repair in Hepatocellular Carcinoma. | Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Targeting p21-High Senescent Kupffer Cells Nanotherapeutically Potentiates Antitumor Immunity in Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombus. | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Bile acid retention in efferocytic macrophages shapes their inflammatory status during cholangitis. | J Exp Med | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Hepatitis B virus promotes hepatocellular carcinogenesis by activating IL-6-dependent tumor-macrophage crosstalk and M2-like macrophage polarization. | J Biol Chem | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Salmonella vector creates de novo parvovirus that reduces solid tumors and forms antitumor immune memory. | Cell Rep Med | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Dual Specificity Phosphatase 4 Enhances Immunotherapy Response by Inhibiting TGF-β1 Secretion in Hepatocellular Carcinoma. | Cancers (Basel) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Hepatic Stellate Cell-Specific METTL3 Deficiency Promotes Hepatocellular Carcinoma Progression via BMP10-SMAD1/5/8 Signaling. | Cancer Res Commun | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Tumor-Intrinsic ARHGEF3 Enhances Antitumor Immunity by Promoting T-Cell Infiltration and Limiting Myeloid Cell-Mediated Immunosuppression. | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Sunitinib induces immunogenic cell death through eIF2α phosphorylation to potentiate immunotherapy in HCC. | iScience | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Laparoscopic Delivery of a MnO2-P-ICG Patch for Photodynamic Therapy and NK Cell-Driven Immunotherapy in Hepatocellular Carcinoma. | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Smartly Assembled near-Micron RF-Responsive Agents Bridge Transarterial Embolization and Immunothermal Potentiation. | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Ginkgolic acid targets HSPA8 to trigger ferroptosis in hepatocellular carcinoma via chaperone-mediated autophagy-dependent GPX4 degradation. | Pharm Biol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Loss of Ezh2 promotes M2-like macrophage polarization in hepatocellular carcinoma. | iScience | 2026 | Its Methods give the RRID and name the line | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_0327/papers